These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 23657012)

  • 41. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.
    Ghiorzo P; Pensotti V; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bonelli L; Borgonovo G; Bruno W; Gozza A; Gargiulo S; Mastracci L; Nasti S; Palmieri G; Papadia F; Pastorino L; Russo A; Savarino V; Varesco L; Bernard L; Bianchi Scarrà G;
    Fam Cancer; 2012 Mar; 11(1):41-7. PubMed ID: 21989927
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2.
    Dray E; Etchin J; Wiese C; Saro D; Williams GJ; Hammel M; Yu X; Galkin VE; Liu D; Tsai MS; Sy SM; Schild D; Egelman E; Chen J; Sung P
    Nat Struct Mol Biol; 2010 Oct; 17(10):1255-9. PubMed ID: 20871616
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structural basis for recruitment of BRCA2 by PALB2.
    Oliver AW; Swift S; Lord CJ; Ashworth A; Pearl LH
    EMBO Rep; 2009 Sep; 10(9):990-6. PubMed ID: 19609323
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Somatic structural rearrangements in genetically engineered mouse mammary tumors.
    Varela I; Klijn C; Stephens PJ; Mudie LJ; Stebbings L; Galappaththige D; van der Gulden H; Schut E; Klarenbeek S; Campbell PJ; Wessels LF; Stratton MR; Jonkers J; Futreal PA; Adams DJ
    Genome Biol; 2010; 11(10):R100. PubMed ID: 20942901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PALB2: the hub of a network of tumor suppressors involved in DNA damage responses.
    Park JY; Zhang F; Andreassen PR
    Biochim Biophys Acta; 2014 Aug; 1846(1):263-75. PubMed ID: 24998779
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer.
    Downs B; Kim YC; Xiao F; Snyder C; Chen P; Fleissner EA; Becirovic D; Wen H; Sherman S; Cowan KH; Lynch HT; Wang SM
    Breast Cancer Res Treat; 2015 May; 151(1):219-24. PubMed ID: 25833210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
    Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
    Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
    Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
    BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic exploitation of tumor cell defects in homologous recombination.
    Powell SN; Kachnic LA
    Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression.
    Bouwman P; Drost R; Klijn C; Pieterse M; van der Gulden H; Song JY; Szuhai K; Jonkers J
    J Pathol; 2011 May; 224(1):10-21. PubMed ID: 21404276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PALB2 self-interaction controls homologous recombination.
    Buisson R; Masson JY
    Nucleic Acids Res; 2012 Nov; 40(20):10312-23. PubMed ID: 22941656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A PALB2 germline mutation associated with hereditary breast cancer in Italy.
    Papi L; Putignano AL; Congregati C; Piaceri I; Zanna I; Sera F; Morrone D; Genuardi M; Palli D
    Fam Cancer; 2010 Jun; 9(2):181-5. PubMed ID: 19763884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
    Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.
    Nepomuceno TC; De Gregoriis G; de Oliveira FMB; Suarez-Kurtz G; Monteiro AN; Carvalho MA
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28858227
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers.
    Tumiati M; Munne PM; Edgren H; Eldfors S; Hemmes A; Kuznetsov SG
    Oncogene; 2016 Sep; 35(35):4601-10. PubMed ID: 26820992
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey.
    Cecener G; Guney Eskiler G; Egeli U; Tunca B; Alemdar A; Gokgoz S; Tasdelen I
    Mol Biol Rep; 2016 Nov; 43(11):1273-1284. PubMed ID: 27573125
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.
    Teo ZL; Park DJ; Provenzano E; Chatfield CA; Odefrey FA; Nguyen-Dumont T; ; Dowty JG; Hopper JL; Winship I; Goldgar DE; Southey MC
    Breast Cancer Res; 2013 Feb; 15(1):R17. PubMed ID: 23448497
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
    Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
    BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Breast cancer proteins PALB2 and BRCA2 stimulate polymerase η in recombination-associated DNA synthesis at blocked replication forks.
    Buisson R; Niraj J; Pauty J; Maity R; Zhao W; Coulombe Y; Sung P; Masson JY
    Cell Rep; 2014 Feb; 6(3):553-64. PubMed ID: 24485656
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.
    Biswas K; Das R; Eggington JM; Qiao H; North SL; Stauffer S; Burkett SS; Martin BK; Southon E; Sizemore SC; Pruss D; Bowles KR; Roa BB; Hunter N; Tessarollo L; Wenstrup RJ; Byrd RA; Sharan SK
    Hum Mol Genet; 2012 Sep; 21(18):3993-4006. PubMed ID: 22678057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.